C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Stifel Nicolaus Keeps Their Buy Rating on C4 Therapeutics (CCCC)
Morgan Stanley Maintains C4 Therapeutics(CCCC.US) With Hold Rating, Maintains Target Price $8
Morgan Stanley analyst Terence Flynn maintains $C4 Therapeutics(CCCC.US)$ with a hold rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 63.9%
Express News | C4 Therapeutics Inc : Evercore ISI Raises Target Price to $10 From $9
Hold Rating on C4 Therapeutics Amid Early-Stage Drug Development and Market Caution